Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 4/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29698867 | 1.00 | HTR1A (0.50) | HTR1ASLC6A2SLC6A4SLC6A3KDM1A | |
| SCHEMBL27880809 | 1.00 | HTR1A (0.50) | HTR1ASLC6A2SLC6A4SLC6A3KDM1A | |
| Hydrochloric Acid SCHEMBL3932246 | 0.98 | HTR1A (0.49) | HTR1ASLC6A2SLC6A4SLC6A3KDM1A | |
| Hydrochloric Acid SCHEMBL30467185 | 0.98 | HTR1A (0.49) | HTR1ASLC6A2SLC6A4SLC6A3KDM1A | |
| SCHEMBL2145272 | 0.89 | HTR6 (0.45) | HTR1ASLC6A2CHRNB2CHRNA4 | |
| SCHEMBL233327 | 0.88 | HTR1A (0.61) | HTR1ASLC6A2SLC6A4SLC6A3KDM1A | |
| SCHEMBL30368779 | 0.88 | HTR1A (0.61) | HTR1ASLC6A2SLC6A4SLC6A3KDM1A | |
| Hydrochloric Acid SCHEMBL567764 | 0.87 | HTR6 (0.44) | HTR1ASLC6A2CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL30010417 | 0.86 | HTR2C (0.61) | HTR1ASLC6A2SLC6A4SLC6A3KDM1A | |
| Hydrochloric Acid SCHEMBL1765243 | 0.86 | HTR2C (0.61) | HTR1ASLC6A2SLC6A4SLC6A3KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110072850-A | 3-sulfonyl-5-aminopyridine-2, 4-diol APJ agonists | 百时美施贵宝公司 | 2019-07-30 | — | — | CN | disclosed |
| US-9932340-B2 | Substituted indoles | ABBVIE INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170349589-A9 | Substituted Indoles | ABBVIE INC. (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170174688-A1 | Substituted Indoles | ABBVIE INC. (US) | 2017-06-22 | — | — | US | disclosed |
| EP-3038466-A1 | 2,2-DIFLUORODIOXOLO A2A RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2016-07-06 | — | — | EP | disclosed |
| WO-2015027431-A1 | 2,2-DIFLUORODIOXOLO A2A RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-03-05 | — | — | WO | disclosed |
| WO-2015031221-A1 | 2,2-DIFLUORODIOXOLO A2A RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-03-05 | — | — | WO | disclosed |
| US-8877745-B2 | CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| US-8669266-B2 | Quinoline-carboxamide derivatives as P2Y12 antagonists | SANOFI (FR) | 2014-03-11 | — | — | US | disclosed |
| US-20130123241-A1 | NOVEL CCR2 RECEPTOR ANTAGONISTS, METHOD FOR PRODUCING THE SAME, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
| US-20080221083-A1 | Heterobicyclic metalloprotease inhibitors | HOCHGURTEL MATTHIAS | 2008-09-11 | — | — | US | disclosed |
| US-20080207607-A1 | Heterotricyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-08-28 | — | — | US | disclosed |
| WO-2008021924-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| CN-1150165-C | 1-arylsulfonyl-2-aryl-pyrrolidine derivatives for the treatment of central nervous system disorders | - | 2004-05-19 | — | — | CN | disclosed |
| CN-1345311-A | 1-arenesulfonyl-2-aryl-pyrolidine and piperidine derivatives for treatment of CNS disorders | HOFFMANN LA ROCHE (CH) | 2002-04-17 | — | — | CN | disclosed |
| US-5861416-A | TREATMENT OF ASTHMA OR COUGH | MERRELL PHARMACEUTICALS INC. (US) | 1999-01-19 | — | — | US | disclosed |
| US-5824690-A | TREATING ASTHMA, COUGH | HOECHST MARION ROUSSEL INC. (US) | 1998-10-20 | — | — | US | disclosed |
| US-5140040-A | Alpha-2-adrenergic receptor antagonist; glaucoma; congestive heart failure; hypotensive agents; headaches; metabolic disorders (diabetes, obesity) | ABBOTT LABORATORIES (US) | 1992-08-18 | — | — | US | disclosed |
| US-5128362-A | Antidepressant, antiglaucoma | ABBOTT LABORATORIES (US) | 1992-07-07 | — | — | US | disclosed |
| US-5086074-A | Selective adrenergic receptor antagonists | ABBOTT LABORATORIES (US) | 1992-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221083-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, MMP3, TIMP3 | HTR1A 3162/4885SLC6A2 3951/4885SLC6A4 2981/4885 |
| US-20170174688-A1 | Substituted Indoles | SUV39H2, SUV39H1, IDO1 | HTR1A 208/4885SLC6A2 505/4885SLC6A4 647/4885 |
| US-20170349589-A9 | Substituted Indoles | SUV39H2, SUV39H1, IDO1 | HTR1A 208/4885SLC6A2 505/4885SLC6A4 647/4885 |
| US-20130123241-A1 | NOVEL CCR2 RECEPTOR ANTAGONISTS, METHOD FOR PRODUCING THE SAME, AND USE THEREOF AS MEDICAMENTS | CCR2, CXCR2, CYSLTR2 | HTR1A 669/4885SLC6A2 3731/4885SLC6A4 4575/4885 |
| US-20080207607-A1 | Heterotricyclic metalloprotease inhibitors | MMP13, MMP3, TIMP3 | HTR1A 1527/4885SLC6A2 2890/4885SLC6A4 2321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.